Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Disease crawled date : 2022 - 01 - 06 save search
Freeline Announces FDA Clearance of Investigational New Drug Application for FLT201 for Gaucher Disease Type 1
Published: 2022-01-06 (Crawled : 20:00) - biospace.com/
FRLN | $6.48 0.0% 0
|
Health Technology
|
| O: 32.65%
H: 1.15%
C: -23.85%
flt201 new drug fda clearance application drug disease fda clearance
Vaxcyte Announces FDA Clearance of Investigational New Drug Application for VAX-24 for the Prevention of Invasive Pneumococcal Disease
Published: 2022-01-06 (Crawled : 15:00) - biospace.com/
PPRUF | $358.55 37.56% 1.5K
|
Consumer Non-Durables
|
| O: 2.64%
H: 0.0%
C: -0.39%
PPRUY | $36.0023 -0.11% 220K
|
Manufacturing
|
| O: -0.99%
H: 0.0%
C: -1.16%
PCVX | $60.82 0.33% 0.33% 1.3M
|
Health Technology
|
| O: 4.14%
H: 2.57%
C: -1.0%
STRO | $3.635 -3.58% -3.71% 520K
|
Health Technology
|
| O: -20.18%
H: 0.0%
C: -9.63%
vax-24 new drug fda clearance application drug disease fda clearance pneumococcal
Alterity Therapeutics Granted New US Patent for Compounds for Neurodegenerative Diseases Including Parkinson's and Alzheimer's
Published: 2022-01-06 (Crawled : 13:30) - biospace.com/
ATHE | $2.04 -4.67% -4.9% 54K
|
Health Technology
|
| O: 26.61%
H: 17.14%
C: 5.71%
alzheimer parkinson patent granted therapeutics disease neurodegenerative alzheimer’s grant alzheimer's
Sangamo Announces Transition of SAR445136 Sickle Cell Disease Program From Sanofi to Sangamo
Published: 2022-01-06 (Crawled : 13:30) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: -1.75%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.26%
H: 0.0%
C: 0.0%
SGMO | $0.5143 6.02% 5.68% 1M
|
Health Technology
|
| O: -12.32%
H: 11.95%
C: 9.37%
sar4451 disease cel
Alterity Therapeutics Granted New US Patent for Compounds for Neurodegenerative Diseases Including Parkinson’s and Alzheimer’s
Published: 2022-01-05 (Crawled : 13:27) - alteritytherapeutics.com
ATHE | $2.04 -4.67% -4.9% 54K
|
Health Technology
|
| O: 26.61%
H: 17.14%
C: 5.71%
alzheimer parkinson patent granted therapeutics disease neurodegenerative alzheimer’s grant alzheimer's
Avalo Reports Positive Phase 1b Results for AVTX-002 in Moderate to Severe Crohn's Disease Patients and Presents Additional Program Updates at 2022 Investor Event
Published: 2022-01-06 (Crawled : 13:00) - biospace.com/
AVTX | $11.71 -2.5% -2.56% 68K
|
Manufacturing
|
| O: -11.36%
H: 2.56%
C: -22.44%
avtx-002 phase 1b disease phase 1 positive results phase 2b
New National Survey of People Living with Bipolar I Disorder Provides Insights Into Disease-Related Challenges and the Treatment Journey
Published: 2022-01-06 (Crawled : 12:30) - investor.alkermes.com
ALKS | $23.86 0.42% 0.42% 2.4M
|
Health Technology
|
| O: 0.52%
H: 3.76%
C: 3.29%
treatment order disease
The Signs, Diagnosis and Treatment of Lyme Disease Discussed as Part of New, On-Demand Webinar Hosted by Industry-Leading Quidel Corporation
Published: 2022-01-05 (Crawled : 10:00) - biospace.com/
QDEL | News M | $39.09 2.17% 2.12% 1.1M
|
Health Technology
|
| O: -7.27%
H: 0.0%
C: 0.0%
treatment ema disease corporation diagnostic
NexImmune Announces Formation of Autoimmune and Infectious Diseases Scientific Advisory Board
Published: 2022-01-05 (Crawled : 10:00) - biospace.com/
RCAR | $0.0001 0.0% 2.5K
|
Manufacturing
|
| O: 7.81%
H: 4.32%
C: 1.45%
NEXI | $3.22 -2.42% -2.48% 23K
|
|
| O: 2.24%
H: 1.31%
C: -1.97%
disease infectious disease
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.